Kunishima Munetaka, Kato Daiki, Nakanishi Shuichi, Kitamura Masanori, Yamada Kohei, Terao Keiji, Asano Tomoya
Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University.
Chem Pharm Bull (Tokyo). 2014;62(11):1146-50. doi: 10.1248/cpb.c14-00468.
We studied the specific labeling of streptavidin using the modular method for affinity labeling (MoAL) that we developed based on a catalytic amide-forming reaction using 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) and a tertiary amine catalyst. The primary structures of avidin and streptavidin are significantly different from each other, and streptavidin does not possess an acidic amino acid equivalent to Asp108 of avidin, which is the target acidic amino acid that was labeled using MoAL. However, using biotinylated modular ligand catalysts (MLC) originally designed for labeling avidin, the labeling of streptavidin was found to successfully proceed at Glu51, which is located in a different region. The present study indicates that MoAL is readily applicable to protein labeling without a precise design for MLC. The most important factor for the design of MLC is to ensure that the linker is of sufficient length to connect the ligands to a catalytic site.
我们使用模块化亲和标记方法(MoAL)研究了链霉亲和素的特异性标记,该方法是我们基于使用2-氯-4,6-二甲氧基-1,3,5-三嗪(CDMT)和叔胺催化剂的催化酰胺形成反应开发的。抗生物素蛋白和链霉亲和素的一级结构彼此有显著差异,并且链霉亲和素不具有与抗生物素蛋白的Asp108等效的酸性氨基酸,而Asp108是使用MoAL进行标记的目标酸性氨基酸。然而,使用最初设计用于标记抗生物素蛋白的生物素化模块化配体催化剂(MLC),发现链霉亲和素在位于不同区域的Glu51处成功进行了标记。本研究表明,MoAL很容易应用于蛋白质标记,而无需对MLC进行精确设计。设计MLC的最重要因素是确保连接子有足够的长度将配体连接到催化位点。